Navigation Links
PharmaNet and Anapharm Europe Formally End Joint Venture
Date:1/26/2011

BARCELONA, Spain, Jan. 26, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc. and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

In conjunction with the termination of this relationship, Dr. Maria Cruz Caturla, Anapharm Europe's majority shareholder, has purchased PharmaNet's minority ownership interest, thus becoming the sole owner of the company.

The companies will independently continue to invest in, and provide to clients, bioanalytical services in their respective laboratory facilities. Additionally, to the extent necessary, the companies will provide coordinated support for those client projects undertaken jointly during the term of the joint venture.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

About Anapharm Europe, S.L.

Anapharm Europe is a leading provider of bioanalytical services for the pharmaceutical, biopharmaceutical and generic firms, working with the most prestigious clinical pharmacology units in Spain, the rest of Europe, and around the world. Located in Barcelona, Spain, its GLP-certified laboratory has high-capacity, state-of-the-art equipment and provides high-quality analytical services, tailored to meet specific client needs.


'/>"/>
SOURCE PharmaNet Development Group, Inc.; Anapharm Europe, S.L.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
2. PharmaNets Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics
3. PharmaNet Launches New Brand Identity at Upcoming Industry Conferences
4. PharmaNet Development Group Announces Observational Research Survey
5. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
6. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
7. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
8. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
9. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
10. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
11. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
Breaking Medicine News(10 mins):